drugset / Trial / NCT05119413
Comparison of a New Masterful Preparation to Kligman's Trio in the Treatment of Melasma
RandomizedParallel-groupDouble-blindTreatment
Summary
Kligman's trio remains the gold standard treatment for melasma. It contain hydroquinone which is an effective anti-melanogenic compound but that has poor tolerance and numerous side-effects. Thiamidol has been proven to be at least as effective as hydroquinone and has a very good safety profile. The objective of this study is to compare the Kligman's trio to the same preparation in which hydroquinone is replaced by thiamidol.
Timeline
- Start
- 2021-11-30
- Primary completion
- 2022-09-16
- Completion
- 2022-12-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Hydroquinone | Small molecule | — | Topical |
| Subject | isobutylamido-thiazolyl-resorcinol | Unknown | — | Topical |
| Background | Isotretinoin | Other / unclassified | — | Topical |